Advertisement

Inherited Pancreatic Endocrine Tumors

  • Jens Waldmann
  • Peter Langer
  • Detlef K. Bartsch
Reference work entry

Abstract:

Pancreatic neuroendocrine tumors (PETs) may arise sporadically or in the setting of an inherited tumor syndrome. These syndromes encomprise the multiple endocrine neoplasia type 1 (MEN1), the Von-Hippel-Lindau (VHL)-syndrome and Neurofibromatosis type 1 (NF-1). The prevalence and the different entities of PETs differ significantly between these syndromes resulting in distinct treatment and screening recommendations.

Treatment of PETs in the setting of an inherited tumor syndrome should consider the natural history of the disease, clinical symptoms and the potential for malignant transformation which has to be taken into account individually for every patient.

Keywords

Liver Metastasis Pancreatic Cyst Predictive Genetic Testing Distal Pancreatic Resection Pancreatic Head Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ki Wong F, Burgess J, Nordenskjold M, Larsson C, Tean Teh B: Multiple endocrine neoplasia type 1. Semin Cancer Biol 2000;10(4):299–312.CrossRefPubMedGoogle Scholar
  2. 2.
    Burgess JR, Greenaway TM, Shepherd JJ: Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998;243(6):465–470.CrossRefPubMedGoogle Scholar
  3. 3.
    Wermer P: Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954;16:363–371.CrossRefPubMedGoogle Scholar
  4. 4.
    Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O’Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV: Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Qjm 1996;89(9):653–669.PubMedGoogle Scholar
  5. 5.
    Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT: Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000;79(6):379–411.CrossRefGoogle Scholar
  6. 6.
    Thompson NW: Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am 1998;7(4):881–891.PubMedGoogle Scholar
  7. 7.
    Lowney JK, Frisella MM, Lairmore TC, Doherty GM: Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 1998;124(6):1043–8; discussion 1048–1049.CrossRefPubMedGoogle Scholar
  8. 8.
    Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA, Jr., Norton JA: Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22(6):581–6; discussion 586–587.CrossRefPubMedGoogle Scholar
  9. 9.
    Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS, Harmsen WS, Ilstrup DM: Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 2000;24(11):1437–1441.CrossRefPubMedGoogle Scholar
  10. 10.
    Carty SE, Helm AK, Amico JA, Clarke MR, Foley TP, Watson CG, Mulvihill JJ: The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998;124(6):1106–13; discussion 1113–1114.CrossRefPubMedGoogle Scholar
  11. 11.
    Pipeleers-Marichal M, Donow C, Heitz PU, Kloppel G: Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 1993;17(4):481–488.CrossRefPubMedGoogle Scholar
  12. 12.
    Thompson NW, Lloyd RV, Nishiyama RH, Vinik AI, Strodel WE, Allo MD, Eckhauser FE, Talpos G, Mervak T: MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984;8(4):561–574.CrossRefPubMedGoogle Scholar
  13. 13.
    Brandi ML: Multiple endocrine neoplasia type 1. Rev Endocr Metab Disord 2000;1(4):275–282.CrossRefPubMedGoogle Scholar
  14. 14.
    Donow C, Pipeleers-Marichal M, Schroder S, Stamm B, Heitz PU, Kloppel G: Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 1991;68(6):1329–1334.CrossRefPubMedGoogle Scholar
  15. 15.
    Gibril F, Schumann M, Pace A, Jensen RT: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83(1):43–83.CrossRefGoogle Scholar
  16. 16.
    Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341(9):635–644.CrossRefPubMedGoogle Scholar
  17. 17.
    Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT: Surgery increases survival in patients with gastrinoma. Ann Surg 2006;244(3):410–419.PubMedGoogle Scholar
  18. 18.
    Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT: Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999;17(2):615–630.PubMedGoogle Scholar
  19. 19.
    Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT: Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001;86(11):5282–5293.CrossRefPubMedGoogle Scholar
  20. 20.
    Rasbach DA, van Heerden JA, Telander RL, Grant CS, Carney JA: Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome. Arch Surg 1985;120(5):584–589.PubMedGoogle Scholar
  21. 21.
    Grama D, Skogseid B, Wilander E, Eriksson B, Martensson H, Cedermark B, Ahren B, Kristofferson A, Oberg K, Rastad J, et al.: Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992;16(4):611–8; discussion 618–619.CrossRefPubMedGoogle Scholar
  22. 22.
    Mignon M, Cadiot G: Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. J Intern Med 1998;243(6):489–494.CrossRefPubMedGoogle Scholar
  23. 23.
    Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M: Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005;242(6):757–64; discussion 764–766.CrossRefPubMedGoogle Scholar
  24. 24.
    Lairmore TC, Chen VY, DeBenedetti MK, Gillanders WE, Norton JA, Doherty GM: Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2000;231(6):909–918.CrossRefPubMedGoogle Scholar
  25. 25.
    Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P: Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006;13(4):1195–1202.CrossRefPubMedGoogle Scholar
  26. 26.
    Mignon M, Ruszniewski P, Podevin P, Sabbagh L, Cadiot G, Rigaud D, Bonfils S: Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 1993;17(4):489–497.CrossRefPubMedGoogle Scholar
  27. 27.
    Thakker RV: Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 2000;29(3):541–567.CrossRefPubMedGoogle Scholar
  28. 28.
    Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Jr., Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86(12):5658–5671.CrossRefPubMedGoogle Scholar
  29. 29.
    Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B, Thiefin G, Beckers A, Veyrac M, Proye C, Ruszniewski P, Mignon M: Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999;116(2):286–293.CrossRefPubMedGoogle Scholar
  30. 30.
    Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA, et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108(6):1637–1649.CrossRefPubMedGoogle Scholar
  31. 31.
    Thompson NW: The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med 1995;238(3):269–280.CrossRefPubMedGoogle Scholar
  32. 32.
    Imamura M, Minematsu S, Tobe T, Adachi H, Takahashi K: Selective arterial secretin injection test for localization of gastrinoma. Nippon Geka Gakkai Zasshi 1986;87(6):671–679.PubMedGoogle Scholar
  33. 33.
    MacFarlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT: Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995;118(6):973–979; discussion 979–980.CrossRefPubMedGoogle Scholar
  34. 34.
    Thompson NW: Surgical treatment of the endocrine pancreas and Zollinger-Ellison syndrome in the MEN 1 syndrome. Henry Ford Hosp Med J 1992;40(3–4):195–198.PubMedGoogle Scholar
  35. 35.
    Anlauf M, Perren A, Kloppel G: Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 2007;74(5):279–284.CrossRefPubMedGoogle Scholar
  36. 36.
    Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH: Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991;110(6):998–1004; discussion 1004–1005.PubMedGoogle Scholar
  37. 37.
    Skogseid B, Eriksson B, Lundqvist G, Lorelius LE, Rastad J, Wide L, Akerstrom G, Oberg K: Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991;73(2):281–287.CrossRefPubMedGoogle Scholar
  38. 38.
    Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT: Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989;106(6):1108–1117; discussion 1117–1118.PubMedGoogle Scholar
  39. 39.
    Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006;244(6):845–851; discussion 852–853.CrossRefPubMedGoogle Scholar
  40. 40.
    Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND: Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006;30(5):643–653.CrossRefPubMedGoogle Scholar
  41. 41.
    Skogseid B, Oberg K, Eriksson B, Juhlin C, Granberg D, Akerstrom G, Rastad J: Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J Surg 1996;20(7):872–6; discussion 877.CrossRefPubMedGoogle Scholar
  42. 42.
    Thompson NW: Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998;243(6):495–500.CrossRefPubMedGoogle Scholar
  43. 43.
    Norton JA: Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor. Best Pract Res Clin Gastroenterol 2005;19(5):699–704.CrossRefPubMedGoogle Scholar
  44. 44.
    Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197(1):29–37.CrossRefPubMedGoogle Scholar
  45. 45.
    Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432–445.CrossRefPubMedGoogle Scholar
  46. 46.
    Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA: Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241(5):776–783; discussion 783–785.CrossRefPubMedGoogle Scholar
  47. 47.
    Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22(23):4762–4771.CrossRefPubMedGoogle Scholar
  48. 48.
    Eriksson B, Oberg K: An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32(2):203–208.CrossRefPubMedGoogle Scholar
  49. 49.
    Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38(3):430–438.CrossRefPubMedGoogle Scholar
  50. 50.
    Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch CE: Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006;140(6):968–76; discussion 976–977.CrossRefPubMedGoogle Scholar
  51. 51.
    Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH: von Hippel-Lindau disease. Lancet 2003;361(9374):2059–2067.CrossRefPubMedGoogle Scholar
  52. 52.
    Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, Glenn G, Linehan WM, Alexander HR: Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 1998;124(6):1153–1159.CrossRefPubMedGoogle Scholar
  53. 53.
    Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL: Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology 2002;225(3):751–758.CrossRefPubMedGoogle Scholar
  54. 54.
    Hough DM, Stephens DH, Johnson CD, Binkovitz LA: Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol 1994;162(5):1091–1094.PubMedGoogle Scholar
  55. 55.
    Melmon KL, Rosen SW: Lindau’s Disease. Review of the Literature and Study of a Large Kindred. Am J Med 1964;36:595–617.CrossRefPubMedGoogle Scholar
  56. 56.
    Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45(5):575–578.Google Scholar
  57. 57.
    Rasmussen SA, Yang Q, Friedman JM: Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68(5):1110–1118.CrossRefPubMedGoogle Scholar
  58. 58.
    Okada E, Shozawa T: Von Recklinghausen’s disease (neurofibromatosis) associated with malignant pheochromocytoma. Acta Pathol Jpn 1984;34(2):425–434.PubMedGoogle Scholar
  59. 59.
    Klein A, Clemens J, Cameron J: Periampullary neoplasms in von Recklinghausen’s disease. Surgery 1989;106(5):815–819.PubMedGoogle Scholar
  60. 60.
    Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990;113(1):39–52.PubMedGoogle Scholar
  61. 61.
    Stabile BE, Morrow DJ, Passaro E, Jr.: The gastrinoma triangle: operative implications. Am J Surg 1984;147(1):25–31.CrossRefPubMedGoogle Scholar
  62. 62.
    O’Riordain DS, O’Brien T, van Heerden JA, Service FJ, Grant CS: Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994;18(4):488–493; discussion 493–494.CrossRefPubMedGoogle Scholar
  63. 63.
    Harris GJ, Tio F, Cruz A Jr.: Somatostatinoma: a case report and review of the literature. J Surg Oncol 1987;36:8.Google Scholar
  64. 64.
    O’Brien TD, Chejfec G, Prinz RA: Clinical features of duodenal somatostatinomas. Surgery 1993;114:1144.Google Scholar
  65. 65.
    Eckhauser FE, Colletti LM, Somatostatinoma In Berger HB, Warshaw AL, Carr-Locke D, Russel C, Büchler MW, Neoptolemus JP, Stan MG: The pancreas, Blackwell science, London P, 1276.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jens Waldmann
    • 1
  • Peter Langer
    • 1
  • Detlef K. Bartsch
    • 1
  1. 1.Department of SurgeryUniversity Hospital Marburg and GiessenMarburgGermany

Personalised recommendations